Solid Tumor, Adult
Conditions
Brief summary
This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).
Detailed description
The following methodology applies to all patients: * Treatment cycles will be 28 days in duration with lesions injected every 2 weeks. IMSA101 dose level will remain the same as at the time of the rollover from parent protocol. * ICI dose level and treatment regimen will remain the same as at the time of the rollover from parent protocol, following the labeled instructions. * The same single pre-defined lesion/lesion site (longest diameter ≥ 10 mm and ≤ 50 mm) shall be injected throughout study duration, if possible. Where the original injection site is considered by the investigator to become inaccessible, a second lesion/lesion site shall be selected as a replacement and this shall be used henceforth so long as it is considered accessible. Subsequent injection sites shall be replaced when they are considered inaccessible. * Where no remaining accessible lesions are present and where benefit of IMSA101 therapy is, in the opinion of the investigator, being derived by the patient, continued injections of IMSA101 into the vicinity of an inaccessible lesion or, in the case that a lesion can no longer be radiographically visualized, into the last known location of the non-visible lesion shall be allowed.
Interventions
DRUGIMSA101
Intra-tumoral administration on Days 1 and 15 of every 28-day cycle
DRUGImmune Checkpoint Inhibitor
Administered according to product label
Sponsors
ImmuneSensor Therapeutics Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent and mental capability to understand the informed consent 2. Currently enrolled in parent protocol IMSA101-101 and is receiving IMSA101 treatment 3. Deriving clinical benefit from study treatment, as determined by the investigator 4. Must have fulfilled all required assessments in parent protocol IMSA101-101 5. Male and female patients with reproductive potential must agree to use two forms of highly effective contraception throughout the study
Exclusion criteria
1. Permanently discontinued from IMSA101 treatment in parent protocol IMSA101-101 for any reason other than enrollment in the rollover study 2. Failure to meet the criteria specified in parent protocol IMSA101-101 for continued study treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Drug-related safety | 12 months | Frequency of drug-related SAE by subject |
| Anti-tumor effects | 12 months | Tumor response based on RECIST v1.1 |
Countries
United States
Outcome results
None listed